METABOLISM AND DISPOSITION OF A POTENT AND SELECTIVE GABA-Aα2/3 RECEPTOR AGONIST IN HEALTHY MALE VOLUNTEERSStacey L. Polsky-Fisher, A. David Rodrigues, S. Vickers et al.|Drug Metabolism and Disposition|2006Cited by 10
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancerRichard M. Lush, Anthony W. Tolcher, Mark Stroh et al.|Cancer Chemotherapy and Pharmacology|2012Cited by 2
Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitorMarian Iwamoto, John A. Wagner, Evan Friedman et al.|Cancer Chemotherapy and Pharmacology|2014Cited by 0
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer Richard M. LushAmita PatnaikDaniel SullivanKyriakos P. PapadopoulosMichele Trucksis • Jacqueline McCreaKristine CerchioXiaodong LiMark StrohDiana SelverianKeith Orford • Scot EbbinghausNancy AgrawalMarian IwamotoJohn A. WagnerAnthony TolcherRichard M. Lush, Dohme Corp, Danielle Sullivan et al.|Unknown|2012Cited by 0